Oragenics, Inc.

Equities

OGEN

US6840235005

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:10:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.09 ^USD	0.00%		+0.93%	-80.63%

Apr. 12	North American Morning Briefing : Big Banks Kick -2-	DJ
Mar. 29	Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Thinking about buying stock in TOMI Environmental Solutions, Robinhood Markets, Scworx Corp, United Airlines, or Oragenics?

December 01, 2021 at 10:46 am EST

NEW YORK, Dec. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TOMZ, HOOD, WORX, UAL, and OGEN.

InvestorsObserver (PRNewsfoto/InvestorsObserver)

To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

TOMZ: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=TOMZ&prnumber=120120215
HOOD: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=HOOD&prnumber=120120215
WORX: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=WORX&prnumber=120120215
UAL: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=UAL&prnumber=120120215
OGEN: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=OGEN&prnumber=120120215

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.

InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-tomi-environmental-solutions-robinhood-markets-scworx-corp-united-airlines-or-oragenics-301435290.html

SOURCE InvestorsObserver

Latest news about Oragenics, Inc.

North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	Mar. 18	CI
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	Mar. 05	CI
Top Midday Decliners	Feb. 28	MT
Oragenics CEO Kimberly Murphy Steps Down, Board Chair to Serve as Interim Executive Chair	Feb. 13	MT
Oragenics, Inc. Announces Leadership Transition	Feb. 12	CI
Oragenics, Inc. Announces CEO Changes	Feb. 12	CI
Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion	Feb. 05	CI
Oragenics, Inc. Announces Management Changes	Dec. 29	CI
Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	Dec. 27	CI
Oragenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Oragenics Announces Directorate Appointments	23-10-18	CI
Oragenics, Inc. Announces Board Appointments	23-10-05	CI
Oragenics Signs Cash, Share Deal to Acquire Odyssey Health's Neurological Drug Technology Pipeline	23-10-05	MT
Oragenics, Inc. entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	23-10-04	CI
North American Morning Briefing : Stock Futures, Yields Rise After Shutdown Averted	23-10-02	DJ
Oragenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Oragenics, Inc. announced that it has received $0.85 million in funding	23-08-07	CI
Oragenics, Inc. announced a financing transaction	23-08-03	CI
Oragenics to Develop Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate	23-06-05	MT
Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate	23-06-05	CI
Oragenics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Oragenics, Inc. Auditor Raises 'Going Concern' Doubt	23-04-16	CI

Chart Oragenics, Inc.

Duration

Period

More charts

Company Profile

Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ORAGENICS, INC.	-80.63%	4.88M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.40%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-10.02%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs

Oragenics, Inc.

Equities

OGEN

US6840235005

Biotechnology & Medical Research

Thinking about buying stock in TOMI Environmental Solutions, Robinhood Markets, Scworx Corp, United Airlines, or Oragenics?

Latest news about Oragenics, Inc.

Chart Oragenics, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs